Pegvisomant

Summary

Pegvisomant (CHEMBL1201515) is an approved protein (ATC H01AX01) targeting GHR; indicated across 9 conditions including acromegaly and pituitary gland disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• ATC class: H01AX01
• Targets: 1 (GHR)
• Indications: 9 conditions
• Clinical trials: 29

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201515
Name	Pegvisomant
Type	Protein
Max phase	4
ATC	H01AX01

Also known as: B2036PEG, Pegvisomant, Pegwisomant, Somavent, Somavert, Trovert, PEGVISOMANT

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
GHR	Growth hormone receptor	Antagonist		0%	P10912

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): GHR.

Top Reactome pathways

2 total, by targets touching each:

Pathway	Targets	Genes
Prolactin receptor signaling	1	GHR
Growth hormone receptor signaling	1	GHR

Dominant GO biological processes

GO term	Targets
endocytosis	1
cell surface receptor signaling pathway via JAK-STAT	1
positive regulation of cell population proliferation	1
response to gravity	1
hormone-mediated signaling pathway	1
cytokine-mediated signaling pathway	1
taurine metabolic process	1
receptor internalization	1
response to food	1
regulation of response to nutrient levels	1
response to estradiol	1
cellular response to insulin stimulus	1
cellular response to hormone stimulus	1
regulation of multicellular organism growth	1
positive regulation of multicellular organism growth	1

Indications & clinical

Indications

9 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
acromegaly	4	MONDO:0019933	EFO:1001485
pituitary gland disorder	3	MONDO:0003381	EFO:0009607
polyostotic fibrous dysplasia	3	MONDO:0008274	MONDO:0008274
prostate adenocarcinoma	1	MONDO:0005082	EFO:0000673
sarcoma	1	MONDO:0005089	EFO:0000691
breast neoplasm	1	MONDO:0021100	EFO:0003869
colorectal neoplasm	1	MONDO:0005335	EFO:0004142
lung neoplasm	1	MONDO:0021117	MONDO:0021117

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 29.

Phase distribution

Phase	Trials
Not specified	11
PHASE4	9
PHASE3	5
PHASE2	2
PHASE1	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00068029	PHASE4	COMPLETED	Pegvisomant And Sandostatin LAR Combination Study
NCT00068042	PHASE4	COMPLETED	A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly
NCT00151437	PHASE4	COMPLETED	Canadian Pegvisomant Compassionate Study In Acromegalic Patients
NCT00552851	PHASE4	UNKNOWN	Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant
NCT00595140	PHASE4	COMPLETED	Acute Application of Pegvisomant and Octreotide in Acromegaly
NCT00642720	PHASE4	COMPLETED	Change in Quality of Life After Addition of Weekly 40 mg Pegvisomant/Placebo in Controlled Acromegalic Patients
NCT01278342	PHASE4	COMPLETED	Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients
NCT01701973	PHASE4	COMPLETED	Effect of DPP4 Inhibition on Growth Hormone Secretion
NCT02668172	PHASE4	UNKNOWN	Pasireotide LAR and Pegvisomant Study in Acromegaly
NCT00017927	PHASE3	COMPLETED	A Study of the Effects of Pegvisomant on Growth Hormone Excess in McCune-Albright Syndrome
NCT00143416	PHASE3	COMPLETED	Long Term Study With B2036-PEG
NCT00383708	PHASE3	COMPLETED	Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients
NCT02952885	PHASE3	COMPLETED	Strict IGF-1 Control in Acromegaly
NCT03882034	PHASE3	COMPLETED	Safety and Efficacy of Pegvisomant in Children With Growth Hormone Excess
NCT05470504	PHASE2	RECRUITING	Study of Growth Hormone Inhibition Using Pegvisomant in Severe Insulin Resistance
NCT02023918	PHASE2	COMPLETED	Role of Growth Hormone Antagonism in Modulating Insulin Sensitivity in Subjects With Pre-diabetes
NCT00976508	PHASE1	TERMINATED	Figitumumab Combined With Pegvisomant For Advanced Solid Tumors
NCT01181973	PHASE1	COMPLETED	Safety, Tolerability and Relative Bioavailability of Pegvisomant in Healthy Subjects
NCT05131100	Not specified	RECRUITING	Korean Regulatory Post Marketing Surveillance for Somavert
NCT00476879	Not specified	COMPLETED	Growth Hormone During Fasting.Signaltransduktion in Muscle and Adipose Tissue and Changes in Intrahepatic Lipid Content
NCT00512473	Not specified	COMPLETED	Growth Hormone Signaling in Vivo in Humans
NCT00652379	Not specified	COMPLETED	Co-treatment With Pegvisomant and a Somatostatin Analogue (SA) in SA-responsive Acromegalic Patients
NCT00658879	Not specified	COMPLETED	Long Term Use of Somavert (Pegvisomant) For A Regulatory Post Marketing Commitment Plan
NCT00969644	Not specified	UNKNOWN	The Relationship Between the Growth Hormone (GH)- Insulin Like Growth Factor I (IGF-I) System and the Inflammatory System in Healthy Normal Persons
NCT01261000	Not specified	COMPLETED	Tissue Biomarker for Pegvisomant Action
NCT01538966	Not specified	TERMINATED	Acromegaly Combination Treatment Study
NCT01804413	Not specified	UNKNOWN	Pegvisomant With Glucagon Test to Assess for Adult Growth Hormone Deficiency
NCT02500095	Not specified	COMPLETED	Substrate Metabolism, Growth Hormone Signaling, and Insulin Sensitivity During Fasting
NCT03225040	Not specified	COMPLETED	Bone MicroArchitecture in Acromegaly

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

1 molecules share ≥1 primary target. Top 1 by shared-target count:

Molecule	Source	Status	Shared targets
Enzalutamide	PubChem	Approved	GHR